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BACKGROUND: Although a pathologic complete response (pCR) after neoadjuvant chemotherapy is associated with favourable
outcomes, a small proportion of patients with pCR have recurrence. This study was designed to identify factors predictive of
recurrence in patients with pCR.
METHODS: A total of 449 breast cancer patients received neoadjuvant chemotherapy, and 88 evaluable patients had a pCR, defined as
no evidence of invasive carcinoma in the breast at surgery. The clinical stage was II in 61 patients (69%), III in 27 (31%). All patients
received taxanes and 92% received anthracyclines. Among 43 patients with HER2-positive tumours, 27 received trastuzumab.
Cox regression analyses were performed to identify predictors of recurrence.
RESULTS: Median follow-up was 46.0 months. There were 12 recurrences, including 8 distant metastases. The rate of locoregional
recurrence was 10.4% after breast-conserving surgery, as compared with 2.5% after mastectomy. Multivariate analysis revealed that
axillary metastases (hazard ratio (HR), 13.6; Po0.0001) and HER2-positive disease (HR, 5.0; Po0.019) were significant predictors of
recurrence. Five of six patients with both factors had recurrence. Inclusion of trastuzumab was not an independent predictor among
patients with HER2-positive breast cancer.
CONCLUSION: Our study results suggest that HER2 status and axillary metastases are independent predictors of recurrence in patients
with pCR.
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Neoadjuvant chemotherapy is a widely accepted treatment not only
for locally advanced breast cancer, but also for earlier-stage operable
disease (van der Hage et al, 2001; Bonadonna et al,1 9 9 8 ;B e a ret al,
2003). Mauri et al (2005) performed a meta-analysis of clinical trials
comparing patients who received preoperative chemotherapy with
those who received postoperative chemotherapy. Death, disease
progression, and distant recurrence were equivalent in both the
arms. The main advantages of neoadjuvant chemotherapy included
the evaluation of the in vivo chemosensitivity of tumours in
individual patients; minimisation of micrometastases; and surgical
downstaging of tumours, allowing breast-conserving surgery (BCS)
to be performed in patients who might have otherwise required a
mastectomy. However, the survival advantage of neoadjuvant
chemotherapy appears to be negligible (Fisher et al, 1997;
Bonadonna et al, 1998; Kuerer et al, 2001; Wolmark et al, 2001).
In several studies, a pathologic complete response (pCR),
defined as the absence of invasive tumour in the breast only or
in the breast and axilla, correlates with a far lower risk of
subsequent recurrence, as well as with improved overall survival
(Fisher et al, 1997, 1998; Bonadonna et al, 1998; Morrell et al, 1998;
Kuerer et al, 1999; Chollet et al, 2002). Thus, efforts have been
made to increase pCR rates by using more effective drugs and
treatment regimens (Smith et al, 2002; Buzdar et al, 2005); the
achievement of pCR has become the primary end point of many
clinical studies.
Although a pCR is associated with favourable outcomes in
most patients, some patients with pCR have disease recurrence.
Previous studies have reported 5-year recurrence rates of 13–25%
(Fisher et al, 1998; Morrell et al, 1998; Kuerer et al, 2001; Wolmark
et al, 2001). Only a few studies have examined predictors of
recurrence in patients who have a pCR to neoadjuvant treatment
(Ring et al, 2004; Gonzalez-Angulo et al, 2005; Guarneri et al,
2006). We therefore retrospectively analysed predictive factors of
recurrence in patients with breast cancer who achieved a pCR after
neoadjuvant chemotherapy.
PATIENTS AND METHODS
Patients
This was a retrospective study of 88 evaluable patients with
primary breast carcinoma who had a pCR after receiving neo-
adjuvant chemotherapy at National Cancer Center Hospital, Tokyo
between 1996 and 2006. The follow-up period was completed
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sin December 2008. The locoregional or distant recurrences were
evaluated on physical examination, or by radiological imaging.
Histopathology
All patients were confirmed to have invasive carcinoma histo-
logically by core needle biopsy. Surgical specimens were sectioned
at 7- to 10-mm thick slices, and the pathological response was
evaluated by pathologists specialised in breast pathology. The
histologic type of the primary tumour was classified according to
the General Rules for Clinical and Pathological Recording of Breast
Cancer, The Japanese Breast Cancer Society (2004). The histologic
grade of the tumours was classified according to the Elston–Ellis
classification system (Elston and Ellis, 1991). The patients’ levels of
oestrogen receptor (ER, 1D5; Dako, Glostrup, Denmark), proges-
terone receptor (PgR, 1A6; Novocastra, Newcastle Upon Tyne,
UK), and HER2 (HercepTest, Dako) were measured by immuno-
histochemical (IHC) analysis of paraffin-embedded tissue speci-
mens. Oestrogen receptor and PgR were classified as positive if
more than 10% of cancer cell nuclei were stained, regardless of the
staining intensity. HER2-positive status was defined as IHC (3þ);
more than 10% of cancer cells markedly positive, or positive
results of fluorescence in situ hybridisation (FISH) for HER2
amplification, that is, a HER2/CEP17 signal ratio of 2.0 (Vysis
Pathvysion; Abbott, Chicago, IL, USA). IHC (2þ) tumours, in
which more than 10% of cancer cells were moderately positive,
were excluded from the analysis without performing FISH test.
A wide range of criteria have been used to define pCR, and a
consensus has yet to be reached. In this study, pCR was defined as
no evidence of invasive carcinoma in the breast at the time of
surgery in line with the criteria of the National Surgical Adjuvant
Breast and Bowel Project B-18 (Wolmark et al, 2001) and the
recommendations of Sataloff et al (1995). Because the presence or
absence of residual ductal carcinoma in situ (DCIS) after preope-
rative therapy does not influence long-term rate of local recurrence
or overall survival (Mazouni et al, 2007), we included patients with
residual DCIS in the category of pCR.
Treatment
Neoadjuvant chemotherapy was indicated in patients with clinical
stage II or III primary breast cancer whose tumours were larger
than 3cm. Although the potential benefits of adding taxanes to
anthracycline-based regimens remain controversial in terms of
long-term outcomes (Bear et al, 2006), regimens combining
anthracyclines with taxanes, either sequentially or concomitantly,
are widely used. In this study, neoadjuvant chemotherapy
regimens included (1) four cycles of doxorubicin (DOX,
50mgm
 2) and docetaxel (DTX, 60mgm
 2) (AT), followed by
additional adjuvant treatment with two cycles of AT or four cycles
of intravenous cyclophosphamide, methotrexate, and 5-fluoro-
uracil (CMF); (2) four cycles of fluorouracil (500mgm
 2)/epirubicin
(100mgm
 2)/cyclophosphamide (600mgm
 2)( F E C )a l o n gw i t h
12 weekly cycles of paclitaxel (80mgm
 2); (3) four cycles of
doxorubicin (60mgm
 2)/cyclophosphamide (600mgm
 2)( A C )
along with 12 weekly cycles of paclitaxel (80mgm
 2); (4) twelve
weekly cycles of paclitaxel (80mgm
 2) only; and (5) four cycles of
AC along with four cycles of DTX (60mgm
 2). After November
2002, patients with HER2-positive tumours received trastuzumab
(initially 4mgkg
 1 followed by 2mgkg
 1 weekly) in combination
with paclitaxel for 12 weeks. Trastuzumab was not administered
post-operatively because it had not been approved for use in an
adjuvant setting in Japan until 2007.
As for breast surgery, patients underwent either mastectomy
(n¼40) or BCS (n¼48). Axillary lymph node dissection or
sentinel lymph node biopsy alone was additionally performed.
The decision to perform BCS was based on the ability to remove
residual disease completely with optimal cosmetic results; patient
preference was also considered. Twenty-one patients (24%)
received adjuvant endocrine therapy including tamoxifen, anas-
trozole, or both drugs for 5 years if either the pre-treatment biopsy
specimen or the surgical specimen obtained after chemotherapy
was positive for ER or PgR. We defined surgical margin positive if
the tumour cells were directly exposed to the margin.
Postoperative radiotherapy was administered to 60 patients (68%)
who had either undergone BCS or had locally advanced disease. The
radiotherapy protocol was as follows: after mastectomy, patients with
clinical stage III disease received radiotherapy, delivered in 2Gy
fractions to chest wall and axilla (total dose 50Gy). After BCS, all
patients received radiotherapy, delivered in 2Gy fractions to the breast
(total dose 50Gy). A booster dose was delivered to the tumorectomy
bed if the surgical margin was positive. Regardless of the surgical
methods, patients with four or more positive axillary lymph nodes
received radiotherapy, delivered in 2Gy fractions to subclavicular
region (total dose 50Gy).
Clinical significance of locoregional recurrence after
neoadjuvant chemotherapy
The impact of locoregional recurrence (LRR) survival after
neoadjuvant chemotherapy on survival remains poorly under-
stood. However, patients with LRR after adjuvant chemotherapy,
especially those with ER-negative tumours, have substantially
worse outcomes regardless of axillary node status (Wapnir et al,
2006; Anderson et al, 2009). Among patients who achieved a pCR
in neoadjuvant setting in our study, the ER-negative rate was
73% and higher than that of patients in adjuvant settings. This
suggests the LRR after neoadjuvant chemotherapy might be
a negative prognostic factor.
Statistical analysis
Statistical analyses were performed using SAS, version 9.2
(SAS Institute Inc., Cary, NC, USA). The log-rank test was used
to identify predictive factors associated with recurrence after the
achievement of pCR. Then, variables with P-values of p0.20 on
univariate analysis were included in the multivariate models.
Multivariate analysis with a Cox proportional-hazards model was
used to identify independent predictors in all 88 patients. Models
were selected by stepwise forward analysis, retaining variables
significant at the a¼0.05 level for the final model. The Kaplan–
Meier product-limit method was used to compute recurrence-
free survival according to the number of predictive factors.
Recurrence-free survival was measured from the date of initial
diagnosis to the date of recurrence (including LRR) or the last
follow-up visit. In addition, the relations of recurrence to
clinicopathological factors in the 43 patients with HER2-positive
tumours were also evaluated. A Cox proportional-hazards model
including variables with P-values of p0.05 on univariate analysis
was used to identify independent predictors of recurrence.
RESULTS
Characteristics of patients with relapse
Of 449 patients with breast cancer who received neoadjuvant
chemotherapy, 88 (20%) evaluable patients were identified as
having a pCR. The median follow-up was 46 months (range,
8–115). Table 1 shows the patient and tumour characteristics.
The median age was 54.5 years (range, 29–78). The median
diameter of the primary breast tumour was 45.0mm (range,
25–130). All patients received taxane-based chemotherapy, and
92% also received anthracycline-based therapy.
A total of 12 patients (13.6%) had tumour recurrence (Table 2).
All recurrences were diagnosed within 32 months after initial diag-
nosis. Seven patients died of breast cancer within the follow-up
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speriod. Among the six patients who had LRR, five had received
BCS as primary surgery, and four had DCIS after neoadjuvant
chemotherapy. LRR occurred in 5 of 48 patients (10.4%) after BCS,
as compared with only 1 of 40 patients (2.5%) after mastectomy.
Predictive factors for recurrence in all 88 patients
with pCR
The results of univariate analysis of predictive factors for
recurrence are shown in Table 3. Variables tested for inclusion
in the multivariate model were axillary lymph node metastasis at
surgery, HER2 status (positive vs negative) and stage (III vs II).
After controlling for these factors, axillary lymph node metastasis
(hazard ratio (HR), 13.6; 95% CI, 4.6–63.3; Po0.0001) and HER2-
positive disease (HR, 5.0; 95% CI, 1.3–19.3; Po0.019) remained
significant independent predictors of recurrence (Table 4).
According to the number of independent risk factors (HER2-
positive disease and axillary lymph node metastasis) for recurrence,
the 5-year recurrence-free rate varied between 94.4% for no factor
(n¼36), 89.1% for 1 factor (n¼46), and 0% for 2 factors (n¼6).
Predictive factors for recurrence among 43 patients with
HER2-positive disease
Among 43 patients with HER2-positive breast cancer who had a
pCR, 27 received trastuzumab. The results of the univariate
analysis of predictive factors for recurrence are shown in Table 3.
Variables tested for inclusion in the multivariate model were
axillary lymph node metastasis at surgery, inclusion of trastuzu-
mab, and stage (III). After controlling for these factors, only
axillary lymph node metastasis (HR, 74.6 (8.0–692.9); Po0.0001)
remained a significant independent predictor of recurrence.
DISCUSSION
Because a small proportion of patients with breast cancer have
recurrence after achievement of a pCR, prediction of the risk of
recurrence has an important role in postoperative management.
Our multivariate analysis of all 88 patients with a pCR showed that
axillary lymph node metastasis and HER2-positive disease were
independent predictors of recurrence. Five of the six patients with
both of these factors had recurrence after achieving a pCR in our
study. Such patients may benefit from additional postoperative
therapy and not be optimal candidates for clinical trials with pCR
as the primary end point.
Although pCR in this study was defined as no evidence of
invasive carcinoma only in the breast, the trial of the University of
Texas MD Anderson Cancer Center pCR criteria requires not only
complete response of the primary lesion but also the disappear-
ance of axillary metastasis (Green et al, 2005). We also performed
Cox regression model analysis of 73 patients who satisfied the MD
Anderson pCR criteria (results not shown). On univariate analysis,
tumour diameter (450mm) and grade (3) had P-values of p0.20.
However, no factor was independently significant in the multi-
variate analysis. The reasons for the differences in the results
according to the definitions of pCR were the smaller sample size,
the smaller number of recurrences (only five recurrences), and the
elimination of the large influence of axillary lymph nodes on
recurrence.
Table 1 Patient characteristics
All patients (N¼88)
Characteristic No. of patients
Age, years
p50/450 33/55
Clinical stage
II/IIIA/IIIB,IIIC 61/18/9
Pre-treatment pathology
Invasive ductal/lobular/mucinous/others 85/1/1/1
Nuclear grade
1/2/3/unknown 2/24/61/1
Hormone receptor status
ER or PgR positive/both negative 23/65
HER2 status
Positive/Negative 43/45
Neoadjuvant chemotherapy
FEC-weekly paclitaxel (±trastuzumab) 31 (16 with trastuzumab)
AC-weekly paclitaxel (±trastuzumab) 30 (8 with trastuzumab)
AT (doxorubicin + docetaxel) 19
Weekly paclitaxel (± trastuzumab) 7 (3 with trastuzumab)
AC-docetaxel 1
Surgery
Mastectomy/Breast-conserving surgery 40/48
Abbreviations: FEC¼fluorouracilþepirubicinþcyclophosphamide; AC¼doxorubicinþ
cyclophosphamide; PgR¼progesterone receptor.
Table 2 Characteristics of patients with recurrence
Initial diagnosis Operative information State at recurrence
No. Age Tumour diameter HER2 ER or PgR Ax. M. DCIS BCS LRR Distant M. Brain M. RFS
13 9 9 0           ++ 8
23 3 5 2   +    +   +   26
36 2 5 5 +      ++ +   26
42 9 3 5 + +   ++ ++   30
55 8 4 2 +      ++ +   32
65 5 6 5 +   ++    +   32
76 3 4 9 +   ++   +    18
83 6 3 4   ++ -    +   20
94 9 3 0 +   ++    +   21
10 56 25 +   ++ + +    21
11 50 55 +   +- +   ++ 2 9
12 71 60    ++ + +    32
Abbreviations: Ax. M.¼axillary lymph node metastasis; M.¼metastasis; BCS¼breast-conserving surgery; RFS¼recurrence-free survival (months); LRR¼locoregional
recurrence; ER¼oestrogen receptor; PgR¼progesterone receptor; HER2¼human epidermal growth factor 2; DCIS¼ductal carcinoma in situ.
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predictor of recurrence in patients who had a pCR of their primary
tumours. In contrast, HER2 status was found to be a predictor of
recurrence for the first time. Gonzalez-Angulo et al (2005) studied
predictive factors for distant metastasis in 226 patients with pCR.
Although HER2 positivity was not a significant predictor of
distant metastasis, HER2 status was unknown in 58% of the
patients, and only 5% received taxane-based chemotherapy.
Interactions between HER2 status and paclitaxel have been reported
in an adjuvant setting, especially among patients with ER-negative
tumours (Hayes et al, 2007). In our exploratory study, HER2 status
was assessed by IHC or FISH analyses in all patients, the ER- or
PgR-positive rate was low (26%), and all the patients received
taxane-based therapy. The combination of these factors may have
contributed to the identification of HER2 positivity as a significant
independent predictor of recurrence after the achievement of a pCR.
Buzdar et al (2005, 2007) and Gianni (2008) reported the results
of randomised trials of trastuzumab given with neoadjuvant
chemotherapy to patients with HER2-positive breast cancer,
and the pCR rate was significantly higher than that in the control
arm. However, there are only a few, small randomised trials
Table 3 Univariate analysis of predictive factors for recurrence
All patients (N¼88) HER2 positive (N¼43)
Characteristic No. Patients with recurrence (%) P-value No. Patients with recurrence (%) P-value
Age
450 years old 55 10.9 28 17.9
p50 years old 33 18.2 0.28 15 20 0.83
Tumour diameter
4 50mm 30 20.0 12 25.0
p50mm 58 10.3 0.22 31 16.1 0.44
Clinical stage
II 61 9.8 30 13.3
III 27 22.2 0.09 13 30.8 0.11
ER or PgR
Positive 23 13.0 9 11.1
Negative 65 13.8 0.87 34 20.6 0.45
HER2
Positive 43 18.6
Negative 45 9.1 0.19
Nuclear grade
3 61 14.5 28 21.4
1–2 26 11.5 0.71 15 13.3 0.49
Type of chemotherapy
Anthracycline + taxane 81 13.4 39 18.0
Taxane based 7 28.6 0.38 4 25.0 0.91
Type of chemotherapy
With trastuzumab 27 7.4 27 7.4
Without trastuzumab 61 16.4 0.28 16 37.5 0.015
Surgery
Mastectomy 40 12.5 21 23.8
BCS 48 14.6 0.84 23 13.6 0.48
Residual DCIS
Present 39 15.4 23 21.7
None 49 12.2 0.65 20 15.0 0.50
No. of LNs examined
p10 15 14.7 7 14.3
410 73 13.7 0.93 36 19.4 0.79
Axillary LN status
Node positive 15 46.7 6 83.3
Node negative 73 6.9 o0.001 37 8.1 o0.001
Abbreviations: ER¼oestrogen receptor; PgR¼progesterone receptor; HER2¼human epidermal growth factor receptor 2; pCR¼pathological complete response;
BCS¼breast-conserving surgery; DCIS¼ductal carcinoma in situ;L N¼lymph node.
Table 4 Multivariate analysis of predictors of recurrence (all 88 patients)
Characteristic HR P-value 95% CI
Axillary lymph node metastasis 13.6 o0.0001 4.6–63.3
HER2-positive disease 5.0 0.019 1.3–19.3
Abbreviations: HR¼hazard ratio; CI¼confidence interval; HER2¼human epidermal
growth factor receptor 2.
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neoadjuvant trastuzumab can improve overall survival (Rowan,
2009). Indeed, in our study, the pCR rate in patients with HER2-
positive breast cancer who received neoadjuvant chemotherapy
with trastuzumab was 50% (27 out of 54), which was much higher
than that for the study group as a whole (20%, 88 out of 449).
However, the inclusion of trastuzumab was not a significant
predictor of recurrence on multivariate analysis. This is partly
because trastuzumab was not administered post-operatively. The
optimal duration of trastuzumab in neoadjuvant and adjuvant
setting should be confirmed prospectively in randomised trials.
The demand for BCS is expected to rise as the reported rate of
pCR after BCS increases. However, LRR rates after BCS in patients
who received neoadjuvant chemotherapy in previous studies have
varied from 2.6 to 22.6% (Mauriac et al, 1999; Rouzier et al, 2001;
Peintinger et al, 2006). This wide variability has led to uncertainty,
and the benefits of BCS have been questioned. Objective evaluation
of the safety and effectiveness of BCS has been precluded by the
small numbers of patients who have achieved a pCR, different
criteria for determining whether BCS is indicated, and different
treatment regimens. Mauri et al (2005) performed a meta-analysis
of clinical trials comparing preoperative with postoperative
chemotherapy. Although the proportion of patients with distant
recurrence was equivalent in both arms, LRR was more frequent
in the preoperative chemotherapy arm, with an HR of about 1.2.
In our study, most cases of LRR occurred after BCS, and the
proportion of patients with LRR was 10.4% after BCS, as compared
with only 2.5% after mastectomy. Our study results suggest that
even after achieving a pCR, patients should be carefully followed
up for LRR after BCS.
This study was retrospective and lacked a sufficient number of
patients with recurrence after the achievement of a pCR to allow us
to make firm recommendations for a given treatment option.
Despite these limitations, some tentative conclusions can be
drawn. First, our retrospective analysis showed that HER2-positive
disease and axillary metastasis were independent predictors of
recurrence after the achievement of a pCR at the primary site in
response to neoadjuvant chemotherapy. This finding suggests that
patients with HER2-positive disease and axillary metastasis may be
candidates for more aggressive adjuvant therapy even after the
achievement of a pCR, but this assumption must be confirmed in
future clinical trials. Second, the inclusion of trastuzumab in
regimens for neoadjuvant chemotherapy might not be predictive
of recurrence, even though the rate of pCR among patients
who received trastuzumab was much higher than that among all
patients who received neoadjuvant chemotherapy. Third, the rate
of LRR was higher after BCS than after mastectomy. Patients who
undergo BCS should thus be closely followed up for LRR.
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